Obesity Drug Battleground: Wins for Clinicians and Patients? (Medscape)

Eli Lilly’s tirzepatide (Zepbound/Mounjaro) and Novo Nordisk’s semaglutide (Wegovy/Ozempic) are locked in a battle shaping the future of obesity care. Early head-to-head data gives Lilly an edge, but prescribing remains a mix of insurance hurdles, patient complications, and trial-and-error. Oral formulations are on the horizon, with convenience likely to sway patient preference—but efficacy, safety, and coverage remain uncertain. As experts caution, the competition could bring innovation and access—or leave costs and insurance barriers firmly in place.